Prostate Cancer: A Comprehensive Perspective

Section 1: Basic Scientific Foundation.- 1. Development, Applied and Surgical Anatomy of the Prostate.- 2. Molecular Biology and Prostate Cancer.- 3. Endocrine Mechanisms, Androgen Receptor and Carcinogenesis, Hormone Escape.- 4. Molecular Mechanisms of Castrate Resistant Prostate Cancer.- 5. Immunologic Aspects of Prostate Cancer.- 6. Stem Cells in Carcinogenesis of the Prostate.- 7. Murine Models of Prostate Cancer.- 8. Prostate Cancer and the Metabolic Syndrome.- 9. Inflammation and Cancer of the Prostate.- 10. HIV and Prostate Cancer.- 11. Prostate Cancer Genetics.- 12. Gene Expression Profiling and Somatic Genome Changes.- 13. The Proteomic Approach to Prostate Cancer.- 14. Epigenetic Changes in Prostate Cancer.- 15. Biomarkers of Potential Therapeutic Value.- 16. Prostate Tissue Banking.- 17. Molecular Imaging in Diagnostics.- 18. Molecular Risk Profiling.- 19. Premalignant Lesions of the Prostate.- 20. The Pathology of Prostatic Carcinoma.- 21. The Pathology of Non-Epithelial Tumors of the Prostate.- 22. Neuroendocrine Prostate Cancer.- Section 2: Epidemiology, Screening, and Chemoprevention.- 23. Epidemiology of Prostate Cancer.- 24. Racial Disparities and the Global Picture.- 25. Natural History of Prostate Cancer.- 26. Population-Based Health Systems as a Foundation for Prostate Cancer Control Research: The Cancer Research Network.- 27. Screening for Prostate Cancer.- 28. Next Generation Screening Tests.- 29. Diet and Prostate Cancer: A Holistic Approach to Management.- 30. Estrogens in Prostate Cancer.- 31. Vitamin D and Prostate Cancer.- 32. The Role of 5a-Reductase Inhibitors (5-ARIs) in Prostate Cancer Chemoprevention.- 33. Other Pharmaceutical Agents in the Chemoprevention of Prostate Cancer.- Section 3: Diagnosis and Staging.- 34. Early-Detection and Patient Risk Stratification in Prostate Cancer.- 35. Tumor Markers.- 36. Prostate Specific Membrane Antigen-Based Diagnostics.- 37. Prostate Specific Membrane Antigen-Based Therapeutics.- 38. Presentation and Symptomatology of Prostate Cancer.- 39. The Role of Ultrasonography.- 40. The Use of Magnetic Resonance Imaging in the Management of Prostate Cancer.- 41. The Role of Functional Magnetic Resonance Imaging Techniques.- 42. Prostate Biopsy.- 43. The Staging of Prostate Cancer.- 44. Nuclear Medicine in Prostate Cancer.- 45. Nanotechnology and Prostate Cancer.- Section 4: Risk Assessment and Decision-Making Strategies for Localized Prostate Cancer.- 46. Disease Risk Stratification.- 47. Nomograms in Prostate Cancer.- 48. Comparative Effectiveness of Treatment Alternatives for Localized Prostate Cancer.- Section 5: Management of Localized Disease.- 49. Radical Treatment for Localized Disease: An Overview of Options and Strategies for Decision Making.- 50. Quality of Life and Management of Localized Disease.- 51. Active Surveillance for Favorable-Risk Prostate Cancer.- 52. Anesthesia for Robotic-Assisted Prostatectomy.- 53. Retropubic Radical Prostatectomy: The Technique.- 54. Retropubic Radical Prostatectomy: The Results.- 55. Radical Perineal Prostatectomy.- 56. Laparoscopic Radical Prostatectomy: The Technique.- 57. Laparoscopic Radical Prostatectomy: The Results.- 58. Robotic Assisted Radical Prostatectomy: The Technique.- 59. Lymph Node Dissection in Prostate Cancer Surgery.- 60. External Beam Radiotherapy for Low Risk Prostate Cancer.- 61. Prostate Brachytherapy: Low Dose Rate.- 62. Prostate Brachytherapy: High Dose Rate.- 63. Intensity Modulated Radiotherapy.- 64. Proton Beam Therapy and Novel Radiotherapeutic Approaches to the Treatment of Prostate Cancer.- 65. Prostate Cryotherapy.- 66. Focal Therapies for Localized Prostate Cancer.- Section 6: Failure and Management of Recurrent, Locally Advanced, and Advanced Disease.- 67. Biochemical Failure in Prostate Cancer.- 68. The Phenomenon of PSA Bounce After Radiation Therapy.- 69. Management of Locally Recurrent Disease.- 70. Management of High Risk/Locally Advanced Disease.- 71. Radiotherapy Plus Hormonal Therapy.- 72. Watchful Waiting in Advanced Prostate Cancer.- 73. Androgen and Androgen Receptor Directed Therapy as Initial Treatment for Prostate Cancer.- 74. Hormone-Based Therapies for Castration Resistant Prostate Cancer.- 75. Toxicity of Androgen Deprivation Therapy in Hormone Sensitive Prostate Cancer.- 76. Chemotherapy and Novel Systemic Approaches in the Treatment of Metastatic Castration Resistant Prostate Cancer.- 77. Immunotherapy.- 78. Bone Health: Prevention of Skeletal Related Events and Palliative Care.- Section 7: Outcomes and Complications After Treatment.- 79. Assessment of Treatment Outcomes Following Prostate Cancer Therapy.- 80. Urinary Incontinence.- 81. Erectile Dysfunction.- 82. Immediate/Early Surgical Complications.- 83. Population-Based Outcomes Following Treatment of Clinically-Localized Prostate Cancer.- 84. Management of Radiation Adverse Effects.- 85. Management of Complications Following Minimally Invasive Prostate Cancer Therapy.- Section 8: Management of Emergencies and Palliative Care.- 86. Prostate Cancer Emergencies.- 87. Management of Bone Metastases.- 88. Pain Relief in Metastatic Cancer.- 89. The Psycho-Social Impact of Prostate Cancer.- 90. Nursing Issues in Prostate Cancer.